Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses

Table 2 Baseline characteristics of the enrolled patients

	MPS (n = 26)	IA (n = 16)	p
Age, yrs, median (IQR)	38 (27–47)	32 (23–45)	0.265*
Female patients, n (%)	19 (73)	10 (63)	0.510^#
EDSS at baseline (IQR)	2.5 (2–3.5)	3 (2–4)	0.112*
Patients with first demyelinating event, n (%)	15 (65)	9 (56)	0.745^#
Patients with DMT, n (%)
None	19 (73)	11 (69)
Basic	2 (8)	1 (6)
Escalation	5 (19)	4 (25)	0.869^#
Duration since relapse onset, days, median (IQR)
To initiation therapy	5(4–7)	6 (4–8)	0.592*
To escalation therapy	17 (15–20)	17 (15–21)	0.507*
Duration from discharge to follow-up, days, median (IQR)	94 (85–103)	89 (84–94)	0.102*
Relapse category, n (%)
Visual	14 (54)	8 (50)
Motor	7 (27)	6 (38)
Sensory	5 (19)	2 (13)	0.758^#

MPS methylprednisolone, IA immunoadsorption. IQR interquartile range, EDSS expanded disability status scale, DMT disease-modifying treatment. Continuous data were evaluated using the Mann–Whitney rank sum test (*). Categorical data were tested using Fisher’s exact test (^#)

ISSN: 1742-2094